Search

everythinglearnresearchcommunity

for

Search:↓

Guselkumab significantly improves quality of life for people with moderate to severe psoriasis.

Guselkumab effectively treats skin reactions caused by adalimumab in certain conditions.

Guselkumab significantly improves psoriasis symptoms within 12 weeks.

Guselkumab effectively reduces fatigue in Psoriatic Arthritis patients over two years.

In 2019, dermatology and venereology improved skin cancer imaging, advanced in treating skin conditions like psoriasis, and explored the skin microbiome's role in diseases.

Cutaneous angiosarcomas require a combined treatment approach, but prognosis is generally poor.

Ixekizumab helps improve life quality, physical ability, and work performance in patients with psoriatic arthritis who haven't used biologic drugs before.

New therapies for rare skin diseases show promise but need more research.

Acitretin may cause salivary gland inflammation.

Ixekizumab effectively treats generalized pustular psoriasis.

Alopecia areata involves immune activation in the scalp, suggesting treatments targeting TH1, TH2, and IL-23 pathways.

Targeting the IL-23/IL-17 pathway effectively treats several inflammatory skin diseases.

COVID-19 can cause skin issues like rashes and "COVID toes," and people with skin conditions should adjust their treatments if they get the virus.

Hidradenitis suppurativa is caused by genetic factors, inflammation, bacteria, hormones, and lifestyle factors like obesity and smoking.

There are still challenges in diagnosing and treating chronic skin diseases, but there is hope for future improvements.

New treatments for a chronic skin condition show promise, but individualized plans are crucial due to varying responses.

Patients with chronic skin conditions on systemic treatments did not have worse COVID-19 outcomes and could resume their treatments after recovery.

New treatments targeting immune pathways show promise for severe hair loss but need more research for safety and effectiveness.

Higher fiber intake may reduce psoriasis severity, but more research is needed for effective dietary strategies.

The new FDA labeling rules provide more detailed drug safety information for pregnant and breastfeeding women, but more data is needed on the risks of many dermatologic drugs.

Stopping adalimumab and starting methotrexate with topical treatments improved the woman's scalp psoriasis and hair regrew.

Secukinumab for psoriasis may cause hair loss.

Microsponges delivery system is a safe, versatile method for controlled drug release in various treatments.

Machine learning can predict symptoms and quality of life in chronic skin disease patients using smartphone app data, and shows that app use varies with patient characteristics.

Tildrakizumab may cause alopecia areata, but stopping it and using corticosteroids can regrow hair.

Certain drugs may cause vitiligo, so patients should be monitored.

More research is needed to find the best treatment for dissecting cellulitis of the scalp.

Semaglutide may help some skin disorders but can also cause skin issues.

GLP-1 agonists may help treat certain skin conditions.